RxDoctor Payments Data

Bryan Burns, MD

Gastroenterology · Trumbull, CTNPI 1790748739

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 17 payments — averaging $63.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • QOL Medical, LLC$525
  • AbbVie$421
  • Sanofi$85
  • Takeda Pharmaceuticals U.S.A., Inc.$22
  • E.r. Squibb & Sons, L.L.C.$16
  • Johnson & Johnson$12

What the payments were for

  • Speaking & faculty fees$40037%
  • Food & beverage$65360%
  • Education$283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 30th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$85,157
Medicare patients
362
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide87$76,111
CreonLipase/Protease/Amylase25$38,275
Dexlansoprazole DrDexlansoprazole36$12,714
MotegrityPrucalopride Succinate14$11,870
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates157$9,407
Sucralfate64$8,114
Omeprazole461$7,755
Lansoprazole31$7,356
Mesalamine15$6,738
SutabSod Sulf/Pot Chloride/Mag Sulf34$5,502
Colestipol Hcl60$4,468
Budesonide EcBudesonide29$4,398
Pantoprazole Sodium168$2,567
CholestyramineCholestyramine (With Sugar)19$2,535
Esomeprazole Magnesium30$1,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$421$114,386112 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$22$11,87014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →